Invesco’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Invesco’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-359,749	Closed	-$38.6M	–	4010
2023 Q1	$38.6M	Buy	359,749 +76,603	+27%	+$8.82M	0.01%	1061
2022 Q4	$31.1M	Sell	283,146 -5,406	-2%	-$351K	0.01%	1139
2022 Q3	$17M	Buy	288,552 +273,784	+1,854%	+$12.5M	0.01%	1430
2022 Q2	$417K	Buy	14,768 +4,137	+39%	+$120K	﹤0.01%	3424
2022 Q1	$402K	Sell	10,631 -51,219	-83%	-$2.02M	﹤0.01%	3505
2021 Q4	$2.44M	Buy	+61,850	New	+$1.94M	﹤0.01%	2726

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Invesco's RXDX Position: Q2 2023 in Review

Invesco sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 359,749 shares — an estimated $38.6M sold.

Invesco first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $38.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Invesco reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Invesco sold 359,749 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $38.6M.
Invesco first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Invesco's Prometheus Biosciences, Inc. Common Stock position peaked at $38.6M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Invesco's 13F filing for Q2 2023, filed 11 Aug 2023.